Tectonic Therapeutic, Inc.
TX45
Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF)
Resolved
279days ago
Phase 1 readout · Oct 1, 2025
What's at stake
Phase 1 trial results for TX45 in Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF) are due Oct 1, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Announced positive topline results from TX45 Phase 1b clinical trial in 14 patients with Group 2 PH-HFrEF.”